Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Prelude Therapeutics’ lead asset won’t be making it to the second act. | Prelude Therapeutics’ lead asset won’t be making it ...

Evotec’s sweeping reorganization has claimed roughly 600 jobs since last March, 200 more than were originally planned under a ...

Blood oxygen tracking is returning to the Apple Watch after an 18-month hiatus, through a software update effective today.  | ...

Shortly after welcoming a new CEO, robot developer Vicarious Surgical reported that it will be delaying the clinical trials ...

A patient has died from kidney injury in a trial of ’ lead antibody-drug conjugate, although the biotech has been advised to ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease (IBD) have been dashed. | Vedanta ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its ...

Using its hub-and-spoke business model, PureTech is launching a new company to develop deupirfenidone (LYT-100), its ...

After the Department of Health and Human Services canceled about $500 million in funding for mR | After HHS abruptly canceled ...